Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Griffiths

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Plos One|February 7, 2015
Phylogeography and conservation genetics of the common wall lizard, Podarcis muralis, on islands at its northern rangeSozos Michaelides, Nina Cornish, Richard Griffiths, et al.
BMJ Open|December 11, 2020
Periprosthetic fractures: the next fragility fracture epidemic? A national observational studyAlex Bottle, Richard Griffiths, Stuart White, et al.
Clinical Prostate Cancer|October 4, 2005
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancerRobert E Hawkins, Luc Daigneault, Richard Cowan, et al.
Intensive Care Medicine|December 13, 2003
Is parenteral nutrition guilty?Peter Varga, Richard Griffiths, René Chiolero, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 10, 2009
ESPEN Guidelines on Parenteral Nutrition: intensive carePierre Singer, Mette M Berger, Greet Van den Berghe, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2011
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer groupRaffaele Califano, Richard Griffiths, Paul Lorigan, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.
Clinical Genitourinary Cancer|August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study ResultsPaul Nathan, Balaji Venugopal, Jamshed Ali, et al.
Current Biology : CB|September 25, 2008
Invasive pathogens threaten species recovery programsSusan F Walker, Jaime Bosch, Timothy Y James, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Plos One|February 7, 2015
Phylogeography and conservation genetics of the common wall lizard, Podarcis muralis, on islands at its northern rangeSozos Michaelides, Nina Cornish, Richard Griffiths, et al.
BMJ Open|December 11, 2020
Periprosthetic fractures: the next fragility fracture epidemic? A national observational studyAlex Bottle, Richard Griffiths, Stuart White, et al.
Clinical Prostate Cancer|October 4, 2005
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancerRobert E Hawkins, Luc Daigneault, Richard Cowan, et al.
Intensive Care Medicine|December 13, 2003
Is parenteral nutrition guilty?Peter Varga, Richard Griffiths, René Chiolero, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 10, 2009
ESPEN Guidelines on Parenteral Nutrition: intensive carePierre Singer, Mette M Berger, Greet Van den Berghe, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2011
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer groupRaffaele Califano, Richard Griffiths, Paul Lorigan, et al.
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.
Clinical Genitourinary Cancer|August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study ResultsPaul Nathan, Balaji Venugopal, Jamshed Ali, et al.
Current Biology : CB|September 25, 2008
Invasive pathogens threaten species recovery programsSusan F Walker, Jaime Bosch, Timothy Y James, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
Pageof 5